Abstract

Coronavirus disease 2019 (COVID-19) is still challenging health care systems worldwide. Over time, it has become clear that respiratory disease is not the only important entity as critically ill patients are also more prone to develop complications, such as acute cardiac injury. Despite extensive research, the mainstay of treatment still relies on supportive care and targeted therapy of these complications. The development of a prognostic model which helps clinicians to diverge patients to an appropriate level of care is thus crucial. As a result, several prognostic markers have been studied in the past few months. Among them are the cardiac biomarkers, especially cardiac troponins T/I and brain natriuretic peptide, which seem to have important prognostic values as several reports have confirmed their strong association with adverse clinical outcomes and death. The use of these biomarkers as part of a prognostic tool could potentially result in more precise risk stratification of COVID-19 patients and divergence to an adequate level of care. However, several caveats persist causing international guidelines to still recommend in favour of a more conservative approach to cardiac biomarker testing for prognostic purposes.

摘要

2019 年冠状病毒病 (COVID-19) 仍在挑战全世界的医疗保健系统。随着时间的推移，人们越来越清楚，呼吸系统疾病并不是唯一重要的疾病，因为危重患者也更容易出现并发症，例如急性心脏损伤。尽管进行了广泛的研究，但主要的治疗方法仍然依赖于这些并发症的支持性护理和靶向治疗。因此，建立一个预后模型来帮助临床医生将患者分类到适当的护理水平至关重要。因此，在过去的几个月里，人们对一些预后标志物进行了研究。其中包括心脏生物标志物，尤其是心肌肌钙蛋白 T/I 和脑钠尿肽，它们似乎具有重要的预后价值，因为一些报告已证实它们与不良临床结果和死亡密切相关。使用这些生物标志物作为预后工具的一部分可能会导致对 COVID-19 患者进行更精确的风险分层，并达到适当的护理水平。然而，一些警告仍然存在，导致国际指南仍然建议采用更保守的方法进行心脏生物标志物检测以用于预后目的。